Nkarta Inc

NASDAQ: NKTX
$3.89
+$0.18 (+4.9%)
Closing Price on October 11, 2024

NKTX Stock Chart and Intraday Price

NKTX Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO, CA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 630.09M USD
Shares Outstanding 49,072,300
Nkarta Inc is a pioneering biopharmaceutical firm focused on the development of innovative cell therapies for cancer patients. With a keen eye on cellular immunotherapy, Nkarta harnesses chimeric antigen receptors to empower lymphocytes to detect and attack tumor cells. Its leading projects, NKX101 and NKX019, are trailblazing treatments targeting acute myeloid leukemia and B cell malignancies, respectively. Founded in 2015 and based in South San Francisco, California, Nkarta stands at the forefront of cancer therapy research, collaborating with industry leaders like CRISPR Therapeutics AG to revolutionize patient care.

NKTX Articles

Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying from an NFL team owner and a new CEO.